About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
Article Date
August 18, 2023
This article is featured on another website.
Go to article
Related posts
Browse all articles
October 9, 2026
Shaping the Next Era of Global Biomanufacturing: Chime Biologics Brings Its “GMP” Vision to CPHI Milan 2026
October 9, 2026
Shaping the Next Era of Global Biomanufacturing: Chime Biologics Brings Its “GMP” Vision to CPHI Milan 2026
October 30, 2026
Labiotech – ESMO 2026: Readouts and Highlights at the Oncology Summit
October 30, 2026
Labiotech – ESMO 2026: Readouts and Highlights at the Oncology Summit